Giuseppe Naso

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

The clinician's perspective on the 21-gene assay in early breast cancer.

The clinician's perspective on the 21-gene assay in early breast cancer.

Journal: Oncotarget
Published: September 11, 2021

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.

Journal: Journal of personalized medicine
Published: November 10, 2020

Multigene tests for breast cancer: the physician's perspective.

Multigene tests for breast cancer: the physician's perspective.

Journal: Oncotarget
Published: November 03, 2020

Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.

Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.

Journal: Future oncology (London, England)
Published: December 19, 2019

Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.

Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.

Journal: Clinical breast cancer
Published: December 11, 2019

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.

Journal: NPJ breast cancer
Published: November 11, 2019

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.

Journal: Clinical breast cancer
Published: July 02, 2019

Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.

Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.

Journal: BMC cancer
Published: April 17, 2018

Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents.

Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents.

Journal: Anticancer research
Published: February 26, 2018

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

Journal: BioMed research international
Published: August 08, 2017

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.

Journal: Tumori
Published: August 02, 2016

The promise of liquid biopsy in cancer: a clinical perspective.

The promise of liquid biopsy in cancer: a clinical perspective.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: November 07, 2015
Showing 1-12 of 19

Last Updated: 09/26/2026